

Article Navigation

**2200 Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer**

[F. Lordick](#) [M. Schuler](#) [S-E. Al-Batran](#) [Z. Zvirbule](#) [G. Manikhas](#) [A. Rusyn](#) [Y. Vinnyk](#) [I. Vynnychenko](#) [N. Fadeeva](#) [M. Nechaeva](#) ... [Show more](#)

Ann Oncol (2016) 27 (suppl\_9): mdw582.001.

**DOI:** <https://doi.org/10.1093/annonc/mdw582.001>

**Published:** 20 December 2016

**Background:** Claudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity. FAST investigated CLDN18.2 tumor expression and therapy with IMAB362 in combination with first line chemotherapy in pts with advanced gastric and GEJ cancer.

**Methods:** Pts with advanced gastric and GEJ cancer were centrally evaluated for CLDN18.2 by immunohistochemistry (CLAUDETECT18.2® Kit). CLDN18.2 expression of ≥ 2+ in ≥ 40% tumor cells was defined positive. Eligible pts required CLDN18.2+ tumors, an ECOG PS of 0–1, and no medical need for trastuzumab treatment. Pts were randomized 1:1 to first line EOX (epirubicin 50 mg/m<sup>2</sup>, oxaliplatin 130 mg/m<sup>2</sup> d1, and capecitabine 625 mg/m<sup>2</sup> bid, d1–21; qd22) with...

**Issue Section:**

[Gastrointestinal tumours, non-colorectal](#)

© European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).